Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?

While monoclonal antibodies show promise for use in the treatment of a variety of disease states, including cancer, autoimmune disease, and allograft rejection, generation of anti-antibody responses still remains a problem. For example, 50% of the patients who receive OKT3 produce blocking antibodie...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kuus-Reichel, K, Grauer, L S, Karavodin, L M, Knott, C, Krusemeier, M, Kay, N E
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 1994
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC368269/
https://ncbi.nlm.nih.gov/pubmed/8556470
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak